DeepMed Research

Henan Cancer Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1977-01-01

Employees: -

Market Cap: -

Website: http://www.anti-cancer.com.cn

Clinical Trials

ARX788 in HER2-positive Metastatic Breast Cancer Patients

Phase 2

Not yet recruiting

Conditions: HER2-positive, Metastatic Breast Cancer

Interventions: Drug: ARX788

First Posted Date: 2024-10-29

Last Posted Date: 2024-10-29

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 44

Registration Number: NCT06663748

Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

Not Applicable

Recruiting

Conditions: Non-small Cell Lung Cancer
Leptomeningeal Metastasis
EGFR Gene Mutation

Interventions: Drug: furmonertinib

First Posted Date: 2024-10-15

Last Posted Date: 2025-03-06

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 60

Registration Number: NCT06643000

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

Local Injection and Systemic Therapy in the Treatment of NSCLC.

Phase 2

Not yet recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Envafolimab
Drug: recombinant human adenovirus type 5
Drug: Recombinant human endostatin

First Posted Date: 2024-09-30

Last Posted Date: 2024-09-30

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 84

Registration Number: NCT06618391

To Evaluate the Efficacy and Safety of Ipsilateral Supraclavicular Lymph Node Dissection for Breast Cancer Patients

Recruiting

Conditions: Locally Advanced Breast Cancer

Interventions: Procedure: Subclavian lymph node dissection+radiotherapy
Procedure: Simple clavicular region radiotherapy

First Posted Date: 2024-09-20

Last Posted Date: 2024-09-20

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 300

Registration Number: NCT06605521

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined with Capecitabine in the Treatment of Active Brain Metastasis of TNBC

Phase 2

Recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: Utidelone and capecitabine

First Posted Date: 2024-09-19

Last Posted Date: 2024-09-19

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 48

Registration Number: NCT06598046

Locations: 🇨🇳
Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China

First-line Treatment for ES-SCLC with Chemotherapy Combined with PD-1/PD-L1 Inhibitor Sequential Thoracic Radiotherapy

Phase 2

Recruiting

Conditions: Extensive-stage Small-cell Lung Cancer

Interventions: Radiation: Thoracic Radiotherapy

First Posted Date: 2024-09-06

Last Posted Date: 2024-09-06

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 47

Registration Number: NCT06586697

Locations: 🇨🇳
HenanCH, Zhengzhou, Henan, China

Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer

Phase 2

Not yet recruiting

Conditions: Laryngeal Cancer
Hypopharynx Cancer
Laryngeal Neoplasms

Interventions: Drug: chemotherapy TP regimen combined with Tislelizumab

First Posted Date: 2024-08-14

Last Posted Date: 2024-08-14

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 46

Registration Number: NCT06554028

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

RE001 T Cell Injection for the Treatment of KRAS G12V Mutated Solid Tumors

Phase 1

Not yet recruiting

Conditions: KRAS G12V
T Cell Therapy

Interventions: Biological: RE001 T cell

First Posted Date: 2024-08-09

Last Posted Date: 2024-08-09

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 30

Registration Number: NCT06545201

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

RE002 T Cell Injection for the Treatment of KRAS G12D Mutated Solid Tumors

Phase 1

Not yet recruiting

Conditions: T Cell Therapy
KRAS G12D

Interventions: Biological: RE002 T cell

First Posted Date: 2024-08-09

Last Posted Date: 2024-08-09

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 30

Registration Number: NCT06546150

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

Axillary Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With Initial cN1 Breast Cancer

Recruiting

Conditions: Sentinel Lymph Node Biopsy

Interventions: Other: SLNB group

First Posted Date: 2024-07-24

Last Posted Date: 2024-12-17

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 508

Registration Number: NCT06518135

Locations: 🇨🇳
Henan cacer hospital, Henan, Henan, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy